PATIENT CARD

ASPAVELI® (pegcetacoplan)

Important information for patients taking ASPAVELI® (pegcetacoplan)

Reporting suspected adverse reactions after authorisation of the medicinal product is important. Please see inside for information on how to report possible side effects.

INFORMATION FOR PATIENTS

For more information on pegcetacoplan, refer to the pegcetacoplan Patient Information Leaflet.

Pegcetacoplan may increase your risk of getting serious and life-threatening infections. Serious infections may quickly become life-threatening and cause death if not recognised and treated early.

Call your doctor or nurse or get emergency care and show this card right away if you have any of these signs and symptoms of a serious infection:

- headache and a fever
- fever and a rash
- fever with or without shivers or chills
- shortness of breath
- high heart rate
- clammy skin
- headache with a stiff neck or stiff back
- headache with nausea (feeling sick) or vomiting
- eyes sensitive to light
- muscle aches with flu like symptoms
- confusion
- extreme pain or discomfort

Always keep this card with you during treatment and for 12 weeks after your last dose. Your risk of serious infections may continue for several weeks after your last dose.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Patient Information Leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

Side effects should also be reported to Swedish Orphan Biovitrum Ltd by email at medical.info.uk@sobi.com or by calling +44 (0) 800 111 4754.

Show this card to any doctor, nurse or pharmacist involved in your care and if you go to hospital.

Patient name:

Carer name (if required):

Prescriber name:

Prescriber hospital:

Prescriber phone number:

INFORMATION FOR HEALTHCARE PROFESSIONALS

This patient has been prescribed pegcetacoplan. Pegcetacoplan may increase the patient's risk of serious bacterial infections such as *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type B infections.

- Serious bacterial infections may become rapidly life-threatening or fatal if not recognised and treated early.
- Closely monitor patients for early signs and symptoms of serious infection and evaluate immediately if infection is suspected. Promptly treat known infections.
- Contact the patient's prescribing physician (details given in this card) as soon as possible if any serious infection is suspected.

For more information about pegcetacoplan, please refer to the full Summary of Product Characteristics available at https://www.medicines.org.uk/emc/product/13369/smpc.

Sobi and Aspaveli are trademarks of Swedish Orphan Biovitrum AB (publ).

© 2026 Swedish Orphan Biovitrum AB (publ) - All rights reserved.

Swedish Orphan Biovitrum Ltd,
Suite 2, Riverside 3, Granta Park,
Great Abington,
Cambridgeshire, CB21 6AD
www.sobi.com/uk/en

NP-52945 August 2026
Date of MHRA Approval: August 2026

sobi